Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.35 |
| ▸ | NR2E1 | Q9Y466 | 6/20 | 0.35 |
| ▸ | WNT3A | P56704 | 1/20 | 0.34 |
| ▸ | EP300 | Q09472 | 1/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11902358 | 0.84 | PSEN1 (0.44) | — | |
| SCHEMBL759702 | 0.78 | PSEN1 (0.59) | — | |
| SCHEMBL11902750 | 0.72 | MAPK1 (0.42) | WNT3AP2RX7 | |
| SCHEMBL1672664 | 0.71 | WNT3A (0.40) | NR2E1WNT3AMMP13P2RX7 | |
| SCHEMBL24369389 | 0.67 | CYP2E1 (0.50) | NR2E1WNT3AEP300MAOB | |
| SCHEMBL22199019 | 0.61 | CYP2E1 (0.56) | NR2E1MAOB | |
| SCHEMBL11901567 | 0.60 | MAPK1 (0.43) | P2RX7 | |
| SCHEMBL19272800 | 0.59 | CYP1A2 (0.56) | NR2E1EP300MAOB | |
| SCHEMBL18754697 | 0.59 | CYP3A4 (0.56) | NR2E1MAOB | |
| SCHEMBL11902390 | 0.58 | MAPK1 (0.42) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120202787-A1 | Novel Heteroaryl Imidazoles And Heteroaryl Triazoles As Gamma-Secretase Modulators | PFIZER INC. | 2012-08-09 | — | — | US | disclosed |
| US-20120202787-A1 | Novel Heteroaryl Imidazoles And Heteroaryl Triazoles As Gamma-Secretase Modulators | PFIZER INC. | 2012-08-09 | — | — | US | disclosed |
| WO-2011048525-A1 | NOVEL HETEROARYL IMIDAZOLES AND HETEROARYL TRIAZOLES AS GAMMA-SECRETASE MODULATORS | PFIZER INC. (US) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202787-A1 | Novel Heteroaryl Imidazoles And Heteroaryl Triazoles As Gamma-Secretase Modulators | BACE1, BACE2, GSAP | GPR142 1367/4885NR2E1 903/4885WNT3A 1164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.